Medicine

Researchers at Rutgers Institute for Health have been awarded $686,376 in federal funds to study the therapeutic benefits of medical cannabis and any potential side effects or harms from using the plant.

The Minnesota Office of Cannabis Management recently denied petitions to add cannabinoid-infused powders, infused flowers, or concentrated cannabis products as new delivery methods for the state’s medical cannabis program.

The Yale Center for the Science of Cannabis and Cannabinoids is awarding over $600,000 in grants to Yale School of Medicine researchers investigating the impact of cannabis and cannabinoids on neurodevelopment and mental health.

Kentucky is set to open medical cannabis patient certifications on December 1 in preparation for launching the state’s medical cannabis program next year.

The majority of women surveyed by YouGov indicated they would try cannabis products if there were perceived health benefits, with most (16%) saying they were interested in sleep quality improvements.

Proposals under consideration by Pennsylvania’s health secretary would let nurse practitioners and podiatrists recommend patients for the state’s medical cannabis program.

Ukrainian health officials have released the list of conditions that will qualify patients for the country’s new medical cannabis program.

Having access to legal medical cannabis in all 50 U.S. states could save Americans up to $29 billion per year in reduced healthcare expenditures, according to a recent study.

A recent survey by Germany-based medical cannabis company Bloomwell GmBh found that 94% of respondents who consumed cannabis said they did so for at least one medical or health reason.

The Oklahoma Court of Criminal Appeals has ruled that women registered with the state’s medical cannabis program who consume cannabis while pregnant cannot be prosecuted for child neglect.

The head of UCLA’s Semel Institute for Neuroscience and Human Behavior is aiming to convert the institute’s top floor into a rooftop garden, or “living laboratory,” designed to study and facilitate psychedelic-assisted therapy.

The largest school district in Kentucky last week approved a policy allowing students to use prescribed medical cannabis treatments while at school.

British researchers investigating the efficacy of medical cannabis for older patients said that people aged 65+ who are prescribed medical cannabis report experiencing “significant improvements across all measures of well-being.”

Three pharmaceutical companies in Zimbabwe have started to manufacture cannabis medicines under the country’s five-year-old industrial hemp reforms.

Vermont Gov. Phil Scott (R) has allowed a medical cannabis expansion bill to become law without his signature; the shift will give patients access to higher potency products without a sales tax.

Connecticut officials have approved two new conditions — autism spectrum disorder and female orgasmic difficulty/disorder — as qualifying conditions for the state medical cannabis program.

The publicly traded and internationally licensed cannabis company Kaya Holdings Inc. announced this week that it has received a license to administer therapeutic psilocybin products in Oregon.

According to a new study compiled by UK researchers, psilocybin — the naturally occurring psychedelic in so-called “magic mushrooms” — shows promise as an effective treatment for depression.

A recent study found that non-medical cannabis use is “significantly associated with 96% decreased odds” of experiencing cognitive decline in adults aged 45 and older.

A recent review published by a group of Canadian scientists suggests that cannabinoids could play a role in preventing and treating COVID-19 and Long-COVID.

Researchers with the Johns Hopkins University School of Medicine, with the support of a $10 million federal grant, are set to track 10,000 U.S. cannabis patients from the start of their medical cannabis journey through at least a year to better understand the efficacy and effects of cannabis medicine.